{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:14:40Z","timestamp":1789236880558,"version":"build-2803163510"},"reference-count":112,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:00:00Z","timestamp":1736467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40263-024-01153-5","type":"journal-article","created":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T13:42:56Z","timestamp":1736516576000},"page":"305-320","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Repurposing Licensed Drugs with Activity Against Epstein\u2013Barr Virus for Treatment of Multiple Sclerosis: A Systematic Approach"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9889-971X","authenticated-orcid":false,"given":"Vivien","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9610-0668","authenticated-orcid":false,"given":"Fiona C.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6825-9172","authenticated-orcid":false,"given":"David C.","family":"Tscharke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7550-9595","authenticated-orcid":false,"given":"Corey","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2241-0353","authenticated-orcid":false,"given":"Rajiv","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3850-447X","authenticated-orcid":false,"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0988-7827","authenticated-orcid":false,"given":"William D.","family":"Rawlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6277-8887","authenticated-orcid":false,"given":"Andrew R.","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2807-0070","authenticated-orcid":false,"given":"Bruce V.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9278-0603","authenticated-orcid":false,"given":"Julia M.","family":"Morahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2437-2250","authenticated-orcid":false,"given":"Lawrence","family":"Steinman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9995-1700","authenticated-orcid":false,"given":"Gavin","family":"Giovannoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7179-0335","authenticated-orcid":false,"given":"Amit","family":"Bar-Or","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7969-8346","authenticated-orcid":false,"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Drosu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Potter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel","family":"Caswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6885-6771","authenticated-orcid":false,"given":"Erin C.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9029-6663","authenticated-orcid":false,"given":"Suzanne","family":"Hodgkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-3172","authenticated-orcid":false,"given":"Todd A.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9429-4307","authenticated-orcid":false,"given":"Simon A.","family":"Broadley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Australian Anti-EBV Drugs for MS Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,10]]},"reference":[{"key":"1153_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","volume":"13","author":"T Olsson","year":"2017","unstructured":"Olsson T, Barcellos LF, Alfredsson L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol. 2017;13:25\u201336. https:\/\/doi.org\/10.1038\/nrneurol.2016.187.","journal-title":"Nat Rev Neurol"},{"key":"1153_CR2","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1080\/14737175.2021.1978843","volume":"21","author":"A Zarghami","year":"2021","unstructured":"Zarghami A, Li Y, Claflin SB, et al. Role of environmental factors in multiple sclerosis. Expert Rev Neurother. 2021;21:1389\u2013408. https:\/\/doi.org\/10.1080\/14737175.2021.1978843.","journal-title":"Expert Rev Neurother"},{"key":"1153_CR3","doi-asserted-by":"publisher","first-page":"eaav7188","DOI":"10.1126\/science.aav7188","volume":"365","author":"International Multiple Sclerosis Genetics Consortium","year":"2019","unstructured":"International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365:eaav7188. https:\/\/doi.org\/10.1126\/science.aav7188.","journal-title":"Science"},{"key":"1153_CR4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012496","volume":"5","author":"AE Handel","year":"2010","unstructured":"Handel AE, Williamson AJ, Disanto G, et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. PLoS ONE. 2010;5: e12496. https:\/\/doi.org\/10.1371\/journal.pone.0012496.","journal-title":"PLoS ONE"},{"key":"1153_CR5","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/00001648-200105000-00009","volume":"12","author":"MA Hern\u00e1n","year":"2001","unstructured":"Hern\u00e1n MA, Zhang SM, Lipworth L, et al. Multiple sclerosis and age at infection with common viruses. Epidemiology. 2001;12:301\u20136. https:\/\/doi.org\/10.1097\/00001648-200105000-00009.","journal-title":"Epidemiology"},{"key":"1153_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000308","author":"J Endriz","year":"2017","unstructured":"Endriz J, Ho PP, Steinman L. Time correlation between mononucleosis and initial symptoms of MS. Neurol Neuroimmunol Neuroinflamm. 2017. https:\/\/doi.org\/10.1212\/NXI.0000000000000308.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1153_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1177\/1352458520907901","volume":"26","author":"BM Jacobs","year":"2020","unstructured":"Jacobs BM, Giovannoni G, Cuzick J, Dobson R. Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors. Mult Scler. 2020;26:1281\u201397. https:\/\/doi.org\/10.1177\/1352458520907901.","journal-title":"Mult Scler"},{"key":"1153_CR8","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1177\/1352458511433920","volume":"18","author":"KC Simon","year":"2012","unstructured":"Simon KC, O\u2019Reilly EJ, Munger KL, et al. Epstein\u2013Barr virus neutralizing antibody levels and risk of multiple sclerosis. Mult Scler. 2012;18:1185\u20137. https:\/\/doi.org\/10.1177\/1352458511433920.","journal-title":"Mult Scler"},{"key":"1153_CR9","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein\u2013Barr virus associated with multiple sclerosis. Science. 2022;375:296\u2013301. https:\/\/doi.org\/10.1126\/science.abj8222.","journal-title":"Science"},{"key":"1153_CR10","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1084\/jem.20071030","volume":"204","author":"B Serafini","year":"2007","unstructured":"Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein\u2013Barr virus infection in the multiple sclerosis brain. J Exp Med. 2007;204:2899\u2013912. https:\/\/doi.org\/10.1084\/jem.20071030.","journal-title":"J Exp Med"},{"key":"1153_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/NEN.0b013e31827bfc62","volume":"72","author":"R Magliozzi","year":"2013","unstructured":"Magliozzi R, Serafini B, Rosicarelli B, et al. B-cell enrichment and Epstein\u2013Barr virus infection in inflammatory cortical lesions in secondary progressive multiple sclerosis. J Neuropathol Exp Neurol. 2013;72:29\u201341. https:\/\/doi.org\/10.1097\/NEN.0b013e31827bfc62.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1153_CR12","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1093\/brain\/awp200","volume":"132","author":"SN Willis","year":"2009","unstructured":"Willis SN, Stadelmann C, Rodig SJ, et al. Epstein\u2013Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009;132:3318\u201328. https:\/\/doi.org\/10.1093\/brain\/awp200.","journal-title":"Brain"},{"key":"1153_CR13","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0b013e3181d865a1","volume":"74","author":"SA Sargsyan","year":"2010","unstructured":"Sargsyan SA, Shearer AJ, Ritchie AM, et al. Absence of Epstein\u2013Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology. 2010;74:1127\u201335. https:\/\/doi.org\/10.1212\/WNL.0b013e3181d865a1.","journal-title":"Neurology"},{"key":"1153_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","volume":"603","author":"TV Lanz","year":"2022","unstructured":"Lanz TV, Brewer RC, Ho PP, et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603:321\u20137. https:\/\/doi.org\/10.1038\/s41586-022-04432-7.","journal-title":"Nature"},{"key":"1153_CR15","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1084\/jem.20072397","volume":"205","author":"JD L\u00fcnemann","year":"2008","unstructured":"L\u00fcnemann JD, Jel\u010di\u0107 I, Roberts S, et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-\u03b3 and IL-2. J Exp Med. 2008;205:1763\u201373. https:\/\/doi.org\/10.1084\/jem.20072397.","journal-title":"J Exp Med"},{"key":"1153_CR16","doi-asserted-by":"publisher","first-page":"eadg3032","DOI":"10.1126\/sciadv.adg3032","volume":"9","author":"OG Thomas","year":"2023","unstructured":"Thomas OG, Bronge M, Tengvall K, et al. Cross-reactive EBNA1 immunity targets alpha-crystallin B and is associated with multiple sclerosis. Sci Adv. 2023;9:eadg3032. https:\/\/doi.org\/10.1126\/sciadv.adg3032.","journal-title":"Sci Adv"},{"key":"1153_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40588-019-00120-9","volume":"6","author":"Q Li","year":"2019","unstructured":"Li Q, Cohen JI. Epstein\u2013Barr virus and the human leukocyte antigen complex. Curr Clin Microbiol Rep. 2019;6:175\u201381. https:\/\/doi.org\/10.1007\/s40588-019-00120-9.","journal-title":"Curr Clin Microbiol Rep"},{"key":"1153_CR18","doi-asserted-by":"publisher","first-page":"1385233","DOI":"10.3389\/fnins.2024.1385233","volume":"18","author":"S Agostini","year":"2024","unstructured":"Agostini S, Mancuso R, Caputo D, et al. EBV and multiple sclerosis: expression of LMP2A in MS patients. Front Neurosci. 2024;18:1385233. https:\/\/doi.org\/10.3389\/fnins.2024.1385233.","journal-title":"Front Neurosci"},{"key":"1153_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1003220","volume":"9","author":"DF Angelini","year":"2013","unstructured":"Angelini DF, Serafini B, Piras E, et al. Increased CD8+ T cell response to Epstein\u2013Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 2013;9: e1003220. https:\/\/doi.org\/10.1371\/journal.ppat.1003220.","journal-title":"PLoS Pathog"},{"key":"1153_CR20","doi-asserted-by":"publisher","first-page":"E197","DOI":"10.3390\/cancers10060197","volume":"10","author":"JS Pagano","year":"2018","unstructured":"Pagano JS, Whitehurst CB, Andrei G. Antiviral drugs for EBV. Cancers (Basel). 2018;10:E197. https:\/\/doi.org\/10.3390\/cancers10060197.","journal-title":"Cancers (Basel)"},{"key":"1153_CR21","doi-asserted-by":"publisher","unstructured":"Cui X, Snapper CM. Epstein Barr virus: development of vaccines and immune cell therapy for EBV-associated diseases. Front Immunol. 2021;12:734471. https:\/\/doi.org\/10.3389\/fimmu.2021.734471.","DOI":"10.3389\/fimmu.2021.734471"},{"key":"1153_CR22","doi-asserted-by":"publisher","unstructured":"Ioannides ZA, Csurhes PA, Douglas NL, et al. Sustained clinical improvement in a subset of patients with progressive multiple sclerosis treated with Epstein\u2013Barr virus-specific T cell therapy. Front Neurol. 2021;12:652811. https:\/\/doi.org\/10.3389\/fneur.2021.652811.","DOI":"10.3389\/fneur.2021.652811"},{"key":"1153_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011487.pub2","author":"M De Paor","year":"2016","unstructured":"De Paor M, O\u2019Brien K, Fahey T, Smith SM. Antiviral agents for infectious mononucleosis (glandular fever). Cochrane Database Syst Rev. 2016. https:\/\/doi.org\/10.1002\/14651858.CD011487.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1153_CR24","doi-asserted-by":"publisher","first-page":"997","DOI":"10.3390\/molecules24050997","volume":"24","author":"G Andrei","year":"2019","unstructured":"Andrei G, Trompet E, Snoeck R. Novel therapeutics for Epstein\u2212Barr virus. Molecules. 2019;24:997. https:\/\/doi.org\/10.3390\/molecules24050997.","journal-title":"Molecules"},{"key":"1153_CR25","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1152\/physrev.1961.41.1.130","volume":"41","author":"J Dobbing","year":"1961","unstructured":"Dobbing J. The blood\u2013brain barrier. Physiol Rev. 1961;41:130\u201388. https:\/\/doi.org\/10.1152\/physrev.1961.41.1.130.","journal-title":"Physiol Rev"},{"key":"1153_CR26","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.antiviral.2019.01.008","volume":"163","author":"RF Chemaly","year":"2019","unstructured":"Chemaly RF, Hill JA, Voigt S, Peggs KS. In vitro comparison of currently available and investigational antiviral agents against pathogenic human double-stranded DNA viruses: a systematic literature review. Antiviral Res. 2019;163:50\u20138. https:\/\/doi.org\/10.1016\/j.antiviral.2019.01.008.","journal-title":"Antiviral Res"},{"key":"1153_CR27","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1128\/JVI.34.2.560-568.1980","volume":"34","author":"BM Colby","year":"1980","unstructured":"Colby BM, Shaw JE, Elion GB, Pagano JS. Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication. J Virol. 1980;34:560\u20138. https:\/\/doi.org\/10.1128\/JVI.34.2.560-568.1980.","journal-title":"J Virol"},{"issue":"Suppl 1","key":"1153_CR28","doi-asserted-by":"publisher","first-page":"S14","DOI":"10.1007\/BF01650106","volume":"15","author":"J Andersson","year":"1987","unstructured":"Andersson J, Sk\u00f6ldenberg B, Henle W, et al. Acyclovir treatment in infectious mononucleosis: a clinical and virological study. Infection. 1987;15(Suppl 1):S14-20. https:\/\/doi.org\/10.1007\/BF01650106.","journal-title":"Infection"},{"key":"1153_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jcv.2010.07.008","volume":"49","author":"PI Rafailidis","year":"2010","unstructured":"Rafailidis PI, Mavros MN, Kapaskelis A, Falagas ME. Antiviral treatment for severe EBV infections in apparently immunocompetent patients. J Clin Virol. 2010;49:151\u20137. https:\/\/doi.org\/10.1016\/j.jcv.2010.07.008.","journal-title":"J Clin Virol"},{"key":"1153_CR30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/BF00868517","volume":"243","author":"J Lycke","year":"1996","unstructured":"Lycke J, Svennerholm B, Hjelmquist E, et al. Acyclovir treatment of relapsing-remitting multiple sclerosis. J Neurol. 1996;243:214\u201324. https:\/\/doi.org\/10.1007\/BF00868517.","journal-title":"J Neurol"},{"key":"1153_CR31","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1093\/jac\/24.6.947","volume":"24","author":"J Lycke","year":"1989","unstructured":"Lycke J, Andersen O, Svennerholm B, et al. Acyclovir concentrations in serum and cerebrospinal fluid at steady state. J Antimicrob Chemother. 1989;24:947\u201354. https:\/\/doi.org\/10.1093\/jac\/24.6.947.","journal-title":"J Antimicrob Chemother"},{"key":"1153_CR32","unstructured":"GlaxoSmithKline. Australian Product Information Zovirax tablets (2016). https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2010-CMI-04738-3"},{"key":"1153_CR33","doi-asserted-by":"publisher","first-page":"11857","DOI":"10.1128\/JVI.01005-09","volume":"83","author":"Y Hoshino","year":"2009","unstructured":"Hoshino Y, Katano H, Zou P, et al. Long-term administration of valacyclovir reduces the number of Epstein\u2013Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J Virol. 2009;83:11857\u201361. https:\/\/doi.org\/10.1128\/JVI.01005-09.","journal-title":"J Virol"},{"key":"1153_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1212\/wnl.58.1.31","volume":"58","author":"E Bech","year":"2002","unstructured":"Bech E, Lycke J, Gadeberg P, et al. A randomized, double-blind, placebo-controlled MRI study of anti-herpes virus therapy in MS. Neurology. 2002;58:31\u20136. https:\/\/doi.org\/10.1212\/wnl.58.1.31.","journal-title":"Neurology"},{"key":"1153_CR35","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1191\/1352458505ms1185oa","volume":"11","author":"JE Friedman","year":"2005","unstructured":"Friedman JE, Zabriskie JB, Plank C, et al. A randomized clinical trial of valacyclovir in multiple sclerosis. Mult Scler. 2005;11:286\u201395. https:\/\/doi.org\/10.1191\/1352458505ms1185oa.","journal-title":"Mult Scler"},{"key":"1153_CR36","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1128\/AAC.47.8.2438-2441.2003","volume":"47","author":"J Lycke","year":"2003","unstructured":"Lycke J, Malmestr\u00f6m C, St\u00e5hle L. Acyclovir levels in serum and cerebrospinal fluid after oral administration of valacyclovir. Antimicrob Agents Chemother. 2003;47:2438\u201341. https:\/\/doi.org\/10.1128\/AAC.47.8.2438-2441.2003.","journal-title":"Antimicrob Agents Chemother"},{"key":"1153_CR37","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1128\/AAC.39.7.1599","volume":"39","author":"TH Bacon","year":"1995","unstructured":"Bacon TH, Boyd MR. Activity of penciclovir against Epstein\u2013Barr virus. Antimicrob Agents Chemother. 1995;39:1599\u2013602. https:\/\/doi.org\/10.1128\/AAC.39.7.1599.","journal-title":"Antimicrob Agents Chemother"},{"key":"1153_CR38","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1053\/jinf.2001.0954","volume":"44","author":"LZ Goldani","year":"2002","unstructured":"Goldani LZ. Treatment of severe infectious mononucleosis with famciclovir. J Infect. 2002;44:92\u20133. https:\/\/doi.org\/10.1053\/jinf.2001.0954.","journal-title":"J Infect"},{"key":"1153_CR39","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1365-2133.2005.07038.x","volume":"154","author":"L Pastore","year":"2006","unstructured":"Pastore L, De Benedittis M, Petruzzi M, et al. Efficacy of famciclovir in the treatment of oral hairy leukoplakia. Br J Dermatol. 2006;154:378\u20139. https:\/\/doi.org\/10.1111\/j.1365-2133.2005.07038.x.","journal-title":"Br J Dermatol"},{"key":"1153_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/13524585231215268","volume":"30","author":"R Dobson","year":"2024","unstructured":"Dobson R, Holden D, Vickaryous N, et al. A phase 2a open-label clinical trial to determine the effect of famciclovir on EBV activity as measured by EBV shedding in the saliva of patients with multiple sclerosis. Mult Scler. 2024;30:63\u201370. https:\/\/doi.org\/10.1177\/13524585231215268.","journal-title":"Mult Scler"},{"key":"1153_CR41","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/095632029700800311","volume":"8","author":"N Borg","year":"1997","unstructured":"Borg N, St\u00e5hle L. Penciclovir pharmacokinetics and distribution to the brain and muscle of rats, studied by microdialysis. Antivir Chem Chemother. 1997;8:275\u20139. https:\/\/doi.org\/10.1177\/095632029700800311.","journal-title":"Antivir Chem Chemother"},{"key":"1153_CR42","unstructured":"Atnahs Pharma Australia Pty Ltd. Australian Product Information\u2014FAMVIR\u00ae (famciclovir). (2020). https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2020-PI-01438-1."},{"key":"1153_CR43","first-page":"1920","volume":"62","author":"W Feng","year":"2002","unstructured":"Feng W, Israel B, Raab-Traub N, et al. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors. Cancer Res. 2002;62:1920\u20136.","journal-title":"Cancer Res"},{"key":"1153_CR44","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1002\/jmv.24870","volume":"89","author":"Z Novali\u0107","year":"2017","unstructured":"Novali\u0107 Z, Verkuijlen SAWM, Verlaan M, et al. Cytolytic virus activation therapy and treatment monitoring for Epstein\u2013Barr virus associated nasopharyngeal carcinoma in a mouse tumor model. J Med Virol. 2017;89:2207\u201316. https:\/\/doi.org\/10.1002\/jmv.24870.","journal-title":"J Med Virol"},{"key":"1153_CR45","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/j.1432-2277.2012.01485.x","volume":"25","author":"B H\u00f6cker","year":"2012","unstructured":"H\u00f6cker B, B\u00f6hm S, Fickenscher H, et al. (Val-)Ganciclovir prophylaxis reduces Epstein\u2013Barr virus primary infection in pediatric renal transplantation: (Val-)Ganciclovir reduces EBV primary infection. Transpl Int. 2012;25:723\u201331. https:\/\/doi.org\/10.1111\/j.1432-2277.2012.01485.x.","journal-title":"Transpl Int"},{"key":"1153_CR46","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.transproceed.2009.02.053","volume":"41","author":"C Venturi","year":"2009","unstructured":"Venturi C, Bueno J, Gavalda J, et al. Impact of valganciclovir on Epstein\u2013Barr virus polymerase chain reaction in pediatric liver transplantation: preliminary report. Transpl Proc. 2009;41:1038\u201340. https:\/\/doi.org\/10.1016\/j.transproceed.2009.02.053.","journal-title":"Transpl Proc"},{"key":"1153_CR47","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/tri.13085","volume":"31","author":"S Ville","year":"2018","unstructured":"Ville S, Imbert-Marcille B-M, Coste-Burel M, et al. Impact of antiviral prophylaxis in adults Epstein\u2013Barr virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study. Transpl Int. 2018;31:484\u201394. https:\/\/doi.org\/10.1111\/tri.13085.","journal-title":"Transpl Int"},{"key":"1153_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1084\/jem.20120696","volume":"211","author":"Z Ding","year":"2014","unstructured":"Ding Z, Mathur V, Ho PP, et al. Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation. J Exp Med. 2014;211:189\u201398. https:\/\/doi.org\/10.1084\/jem.20120696.","journal-title":"J Exp Med"},{"key":"1153_CR49","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s002800050916","volume":"43","author":"BM Serabe","year":"1999","unstructured":"Serabe BM, Murry DJ, Dauser R, et al. Plasma and CSF pharmacokinetics of ganciclovir in nonhuman primates. Cancer Chemother Pharmacol. 1999;43:415\u20138. https:\/\/doi.org\/10.1007\/s002800050916.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1153_CR50","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1128\/CMR.00007-10","volume":"23","author":"R Nau","year":"2010","unstructured":"Nau R, S\u00f6rgel F, Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid\/blood\u2013brain barrier for treatment of central nervous system infections. Clin Microbiol Rev. 2010;23:858\u201383. https:\/\/doi.org\/10.1128\/CMR.00007-10.","journal-title":"Clin Microbiol Rev"},{"key":"1153_CR51","unstructured":"Pharmaco (Australia) Ltd. Australian Product Information\u2014Ganciclovir SXP (ganciclovir). (2018). https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2019-PI-01802-1."},{"key":"1153_CR52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1093\/infdis\/jix263","volume":"216","author":"JE Yager","year":"2017","unstructured":"Yager JE, Magaret AS, Kuntz SR, et al. Valganciclovir for the suppression of Epstein\u2013Barr virus replication. J Infect Dis. 2017;216:198\u2013202. https:\/\/doi.org\/10.1093\/infdis\/jix263.","journal-title":"J Infect Dis"},{"key":"1153_CR53","doi-asserted-by":"publisher","first-page":"2894","DOI":"10.1111\/j.1600-6143.2005.01115.x","volume":"5","author":"DP Funch","year":"2005","unstructured":"Funch DP, Walker AM, Schneider G, et al. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant. 2005;5:2894\u2013900. https:\/\/doi.org\/10.1111\/j.1600-6143.2005.01115.x.","journal-title":"Am J Transplant"},{"key":"1153_CR54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5301\/ejo.5000673","volume":"26","author":"S Boonsopon","year":"2016","unstructured":"Boonsopon S, Maghsoudlou A, Kombo NE, Foster CS. A therapeutic trial of valganciclovir in patients with uveitis and positive Epstein\u2013Barr virus early antigen D IgG titers. Eur J Ophthalmol. 2016;26:30\u20135. https:\/\/doi.org\/10.5301\/ejo.5000673.","journal-title":"Eur J Ophthalmol"},{"key":"1153_CR55","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3390\/molecules26041132","volume":"26","author":"G Andrei","year":"2021","unstructured":"Andrei G, Snoeck R. Advances and perspectives in the management of varicella-zoster virus infections. Molecules. 2021;26:1132. https:\/\/doi.org\/10.3390\/molecules26041132.","journal-title":"Molecules"},{"key":"1153_CR56","doi-asserted-by":"publisher","first-page":"257","DOI":"10.7326\/0003-4819-126-4-199702150-00001","volume":"126","author":"JP Lalezari","year":"1997","unstructured":"Lalezari JP, Stagg RJ, Kuppermann BD, et al. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med. 1997;126:257\u201363. https:\/\/doi.org\/10.7326\/0003-4819-126-4-199702150-00001.","journal-title":"Ann Intern Med"},{"key":"1153_CR57","doi-asserted-by":"publisher","first-page":"12422","DOI":"10.1128\/JVI.02231-13","volume":"87","author":"N Coen","year":"2013","unstructured":"Coen N, Duraffour S, Naesens L, et al. Evaluation of novel acyclic nucleoside phosphonates against human and animal gammaherpesviruses revealed an altered metabolism of cyclic prodrugs upon Epstein\u2013Barr virus reactivation in P3HR-1 cells. J Virol. 2013;87:12422\u201332. https:\/\/doi.org\/10.1128\/JVI.02231-13.","journal-title":"J Virol"},{"key":"1153_CR58","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1038\/sj.onc.1206402","volume":"22","author":"B Abdulkarim","year":"2003","unstructured":"Abdulkarim B, Sabri S, Zelenika D, et al. Antiviral agent Cidofovir decreases Epstein\u2013Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies. Oncogene. 2003;22:2260\u201371. https:\/\/doi.org\/10.1038\/sj.onc.1206402.","journal-title":"Oncogene"},{"key":"1153_CR59","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/jmv.21165","volume":"80","author":"T Yoshizaki","year":"2008","unstructured":"Yoshizaki T, Wakisaka N, Kondo S, et al. Treatment of locally recurrent Epstein\u2013Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir. J Med Virol. 2008;80:879\u201382. https:\/\/doi.org\/10.1002\/jmv.21165.","journal-title":"J Med Virol"},{"key":"1153_CR60","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jcv.2016.04.020","volume":"80","author":"H Takamatsu","year":"2016","unstructured":"Takamatsu H, Araki R, Nishimura R, et al. Epstein\u2013Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation. J Clin Virol. 2016;80:82\u20136. https:\/\/doi.org\/10.1016\/j.jcv.2016.04.020.","journal-title":"J Clin Virol"},{"key":"1153_CR61","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1080\/10428190500254208","volume":"47","author":"C Nozzoli","year":"2006","unstructured":"Nozzoli C, Bartolozzi B, Guidi S, et al. Epstein\u2013Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma. 2006;47:167\u20139. https:\/\/doi.org\/10.1080\/10428190500254208.","journal-title":"Leuk Lymphoma"},{"key":"1153_CR62","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000055132","volume":"24","author":"M H\u00e4nel","year":"2001","unstructured":"H\u00e4nel M, Fiedler F, Thorns C. Anti-CD20 monoclonal antibody (rituximab) and cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement. Oncol Res Treat. 2001;24:491\u20134. https:\/\/doi.org\/10.1159\/000055132.","journal-title":"Oncol Res Treat"},{"key":"1153_CR63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1002715","volume":"8","author":"C Casiraghi","year":"2012","unstructured":"Casiraghi C, Shanina I, Cho S, et al. Gammaherpesvirus latency accentuates EAE pathogenesis: relevance to Epstein\u2013Barr virus and multiple sclerosis. PLoS Pathog. 2012;8: e1002715. https:\/\/doi.org\/10.1371\/journal.ppat.1002715.","journal-title":"PLoS Pathog"},{"key":"1153_CR64","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s41983-020-00260-6","volume":"57","author":"S Mansoor","year":"2021","unstructured":"Mansoor S, Mullane G, Adenan MH, et al. Natalizumab-associated progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS): \u201ca case report from Ireland with review of literature, clinical pitfalls and future direction.\u201d Egypt J Neurol Psychiatr Neurosurg. 2021;57:7. https:\/\/doi.org\/10.1186\/s41983-020-00260-6.","journal-title":"Egypt J Neurol Psychiatr Neurosurg"},{"key":"1153_CR65","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13238","volume":"22","author":"NJ Kim","year":"2020","unstructured":"Kim NJ, Hyun TS, Pergam SA, Issaka RB. Disseminated adenovirus infection after autologous stem cell transplant. Transpl Infect Dis. 2020;22: e13238. https:\/\/doi.org\/10.1111\/tid.13238.","journal-title":"Transpl Infect Dis"},{"key":"1153_CR66","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2165\/00003088-199936020-00004","volume":"36","author":"KC Cundy","year":"1999","unstructured":"Cundy KC. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin Pharmacokinet. 1999;36:127\u201343. https:\/\/doi.org\/10.2165\/00003088-199936020-00004.","journal-title":"Clin Pharmacokinet"},{"key":"1153_CR67","unstructured":"Emcure Pharmaceuticals. Australian Product Information\u2014Empovir (Cidofovir). (2019). https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2018-PI-01541-1."},{"key":"1153_CR68","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/978-3-642-56352-2_11","volume-title":"Immunosurveillance, immunodeficiencies and lymphoproliferations","author":"SH Oertel","year":"2002","unstructured":"Oertel SH, Riess H. Antiviral treatment of Epstein\u2013Barr virus-associated lymphoproliferations. In: Oertel SH, Riess H, editors. Immunosurveillance, immunodeficiencies and lymphoproliferations. Berlin: Springer; 2002. p. 89\u201395."},{"key":"1153_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2022.101363","volume":"25","author":"K Suzuki","year":"2022","unstructured":"Suzuki K, Namba K, Hase K, et al. A case of Epstein\u2013Barr virus acute retinal necrosis successfully treated with foscarnet. Am J Ophthalmol Case Rep. 2022;25: 101363. https:\/\/doi.org\/10.1016\/j.ajoc.2022.101363.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"1153_CR70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/jmv.21383","volume":"81","author":"C Ma","year":"2009","unstructured":"Ma C, Wong CK, Wong BCK, et al. Cytokine responses in a severe case of glandular fever treated successfully with foscarnet combined with prednisolone and intravenous immunoglobulin: cytokines in treated glandular fever. J Med Virol. 2009;81:99\u2013105. https:\/\/doi.org\/10.1002\/jmv.21383.","journal-title":"J Med Virol"},{"key":"1153_CR71","doi-asserted-by":"publisher","first-page":"NP120","DOI":"10.1177\/11206721211006576","volume":"32","author":"M Menean","year":"2022","unstructured":"Menean M, Marchese A, Bordato A, et al. Bilateral acute retinal necrosis during treatment with alemtuzumab for multiple sclerosis. Eur J Ophthalmol. 2022;32:NP120\u20132. https:\/\/doi.org\/10.1177\/11206721211006576.","journal-title":"Eur J Ophthalmol"},{"key":"1153_CR72","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12348-016-0095-y","volume":"6","author":"AB Sood","year":"2016","unstructured":"Sood AB, Kumar G, Robinson J. Bilateral acute retinal necrosis in a patient with multiple sclerosis on natalizumab. J Ophthalmic Inflamm Infect. 2016;6:26. https:\/\/doi.org\/10.1186\/s12348-016-0095-y.","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"1153_CR73","doi-asserted-by":"publisher","first-page":"782","DOI":"10.3389\/fneur.2020.00782","volume":"11","author":"K Breitkopf","year":"2020","unstructured":"Breitkopf K, Aytulun A, F\u00f6rster M, et al. Case report: a case of severe clinical deterioration in a patient with multiple sclerosis. Front Neurol. 2020;11:782. https:\/\/doi.org\/10.3389\/fneur.2020.00782.","journal-title":"Front Neurol"},{"key":"1153_CR74","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1128\/AAC.37.5.1010","volume":"37","author":"UR Hengge","year":"1993","unstructured":"Hengge UR, Brockmeyer NH, Malessa R, et al. Foscarnet penetrates the blood\u2013brain barrier: rationale for therapy of cytomegalovirus encephalitis. Antimicrob Agents Chemother. 1993;37:1010\u20134. https:\/\/doi.org\/10.1128\/AAC.37.5.1010.","journal-title":"Antimicrob Agents Chemother"},{"key":"1153_CR75","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14401","author":"E Rho","year":"2021","unstructured":"Rho E, N\u00e4f B, M\u00fcller TF, et al. Use of letermovir-valganciclovir combination as a step-down treatment after foscarnet for ganciclovir-resistant CMV infection in kidney transplant recipients. Clin Transplant. 2021. https:\/\/doi.org\/10.1111\/ctr.14401.","journal-title":"Clin Transplant"},{"key":"1153_CR76","unstructured":"Link Medical Products. Australian Product Information\u2014Foscavir (Foscarnet). (2020). https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2016-PI-02387-1."},{"key":"1153_CR77","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","volume":"46","author":"KK Biron","year":"2002","unstructured":"Biron KK, Harvey RJ, Chamberlain SC, et al. Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action. Antimicrob Agents Chemother. 2002;46:2365\u201372. https:\/\/doi.org\/10.1128\/AAC.46.8.2365-2372.2002.","journal-title":"Antimicrob Agents Chemother"},{"key":"1153_CR78","doi-asserted-by":"publisher","first-page":"7271","DOI":"10.1128\/JVI.73.9.7271-7277.1999","volume":"73","author":"VL Zacny","year":"1999","unstructured":"Zacny VL, Gershburg E, Davis MG, et al. Inhibition of Epstein\u2013Barr virus replication by a benzimidazole l-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl-1H-benzimidazole. J Virol. 1999;73:7271\u20137. https:\/\/doi.org\/10.1128\/JVI.73.9.7271-7277.1999.","journal-title":"J Virol"},{"key":"1153_CR79","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/rmv.615","volume":"19","author":"MN Prichard","year":"2009","unstructured":"Prichard MN. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol. 2009;19:215\u201329. https:\/\/doi.org\/10.1002\/rmv.615.","journal-title":"Rev Med Virol"},{"key":"1153_CR80","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1128\/AAC.03214-14","volume":"58","author":"S Chou","year":"2014","unstructured":"Chou S, Ercolani RJ, Sahoo MK, et al. Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing. Antimicrob Agents Chemother. 2014;58:4697\u2013702. https:\/\/doi.org\/10.1128\/AAC.03214-14.","journal-title":"Antimicrob Agents Chemother"},{"key":"1153_CR81","doi-asserted-by":"publisher","first-page":"12108","DOI":"10.1128\/JVI.01575-09","volume":"83","author":"F-Z Wang","year":"2009","unstructured":"Wang F-Z, Roy D, Gershburg E, et al. Maribavir inhibits Epstein\u2013Barr virus transcription in addition to viral DNA replication. J Virol. 2009;83:12108\u201317. https:\/\/doi.org\/10.1128\/JVI.01575-09.","journal-title":"J Virol"},{"key":"1153_CR82","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1093\/jac\/dki240","volume":"56","author":"E Gershburg","year":"2005","unstructured":"Gershburg E, Pagano JS. Epstein-Barr virus infections: prospects for treatment. J Antimicrob Chemother. 2005;56:277\u201381. https:\/\/doi.org\/10.1093\/jac\/dki240.","journal-title":"J Antimicrob Chemother"},{"key":"1153_CR83","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.virol.2009.04.007","volume":"389","author":"T Murata","year":"2009","unstructured":"Murata T, Isomura H, Yamashita Y, et al. Efficient production of infectious viruses requires enzymatic activity of Epstein\u2013Barr virus protein kinase. Virology. 2009;389:75\u201381. https:\/\/doi.org\/10.1016\/j.virol.2009.04.007.","journal-title":"Virology"},{"key":"1153_CR84","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1128\/JVI.03505-12","volume":"87","author":"CB Whitehurst","year":"2013","unstructured":"Whitehurst CB, Sanders MK, Law M, et al. Maribavir inhibits Epstein\u2013Barr virus transcription through the EBV protein kinase. J Virol. 2013;87:5311\u20135. https:\/\/doi.org\/10.1128\/JVI.03505-12.","journal-title":"J Virol"},{"key":"1153_CR85","unstructured":"Takeda Pharmaceuticals Australia. Australian Product Information-Livtencity (Maribavir) Tablets. (2022). https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2022-PI-02085-1."},{"key":"1153_CR86","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1128\/AAC.46.8.2373-2380.2002","volume":"46","author":"GW Koszalka","year":"2002","unstructured":"Koszalka GW, Johnson NW, Good SS, et al. Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother. 2002;46:2373\u201380. https:\/\/doi.org\/10.1128\/AAC.46.8.2373-2380.2002.","journal-title":"Antimicrob Agents Chemother"},{"key":"1153_CR87","doi-asserted-by":"publisher","first-page":"12368","DOI":"10.1073\/pnas.2002392117","volume":"117","author":"NC Drosu","year":"2020","unstructured":"Drosu NC, Edelman ER, Housman DE. Tenofovir prodrugs potently inhibit Epstein\u2013Barr virus lytic DNA replication by targeting the viral DNA polymerase. Proc Natl Acad Sci USA. 2020;117:12368\u201374. https:\/\/doi.org\/10.1073\/pnas.2002392117.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1153_CR88","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105444","volume":"82","author":"N Drosu","year":"2024","unstructured":"Drosu N, Bjornevik K, Bilodeau PA, et al. In the era of antiviral trials for MS, the answer lies in the details. Mult Scler Relat Disord. 2024;82: 105444. https:\/\/doi.org\/10.1016\/j.msard.2024.105444.","journal-title":"Mult Scler Relat Disord"},{"key":"1153_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105436","volume":"83","author":"\u00d8 Torkildsen","year":"2024","unstructured":"Torkildsen \u00d8, Myhr K-M, Brugger-Synnes P, Bj\u00f8rnevik K. Antiviral therapy with tenofovir in MS. Mult Scler Relat Disord. 2024;83: 105436. https:\/\/doi.org\/10.1016\/j.msard.2024.105436.","journal-title":"Mult Scler Relat Disord"},{"key":"1153_CR90","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1097\/QAI.0b013e318247ec54","volume":"59","author":"BM Best","year":"2012","unstructured":"Best BM, Letendre SL, Koopmans P, et al. LOW CSF concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr. 2012;59:376\u201381. https:\/\/doi.org\/10.1097\/QAI.0b013e318247ec54.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1153_CR91","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1097\/QAD.0b013e3283489cb1","volume":"25","author":"A Calcagno","year":"2011","unstructured":"Calcagno A, Bonora S, Simiele M, et al. Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood\u2013brainbarrier damage. AIDS. 2011;25:1437\u20139. https:\/\/doi.org\/10.1097\/QAD.0b013e3283489cb1.","journal-title":"AIDS"},{"key":"1153_CR92","unstructured":"Gilead Sciences. Product information for AusPAR Viread; tenofovir disoproxil fumarate. (2013). https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2011-PI-03321-3."},{"key":"1153_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.105396","volume":"83","author":"N Drosu","year":"2024","unstructured":"Drosu N, Levy M. Radiologic and clinical stability in an HIV-negative MS patient after tenofovir: an updated case report. Mult Scler Relat Disord. 2024;83: 105396. https:\/\/doi.org\/10.1016\/j.msard.2023.105396.","journal-title":"Mult Scler Relat Disord"},{"key":"1153_CR94","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jpba.2018.04.035","volume":"156","author":"AJ Ocque","year":"2018","unstructured":"Ocque AJ, Hagler CE, Morse GD, et al. Development and validation of an LC\u2013MS\/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid. J Pharm Biomed Anal. 2018;156:163\u20139. https:\/\/doi.org\/10.1016\/j.jpba.2018.04.035.","journal-title":"J Pharm Biomed Anal"},{"key":"1153_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0226276","volume":"14","author":"L Hermansson","year":"2019","unstructured":"Hermansson L, Yilmaz A, Price RW, et al. Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. PLoS ONE. 2019;14: e0226276. https:\/\/doi.org\/10.1371\/journal.pone.0226276.","journal-title":"PLoS ONE"},{"key":"1153_CR96","doi-asserted-by":"publisher","first-page":"3609","DOI":"10.1073\/pnas.1523686113","volume":"113","author":"D Verma","year":"2016","unstructured":"Verma D, Thompson J, Swaminathan S. Spironolactone blocks Epstein\u2013Barr virus production by inhibiting EBV SM protein function. Proc Natl Acad Sci USA. 2016;113:3609\u201314. https:\/\/doi.org\/10.1073\/pnas.1523686113.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1153_CR97","doi-asserted-by":"publisher","first-page":"13044","DOI":"10.1073\/pnas.2000625117","volume":"117","author":"D Verma","year":"2020","unstructured":"Verma D, Church TM, Swaminathan S. Epstein\u2013Barr virus co-opts TFIIH component XPB to specifically activate essential viral lytic promoters. Proc Natl Acad Sci USA. 2020;117:13044\u201355. https:\/\/doi.org\/10.1073\/pnas.2000625117.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1153_CR98","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2174\/18715273113126660177","volume":"12","author":"S Samanani","year":"2013","unstructured":"Samanani S, Mishra M, Silva C, et al. Screening for inhibitors of microglia to reduce neuroinflammation. CNS Neurol Disord Drug Targets. 2013;12:741\u20139. https:\/\/doi.org\/10.2174\/18715273113126660177.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1153_CR99","doi-asserted-by":"publisher","first-page":"191","DOI":"10.4049\/jimmunol.0802886","volume":"184","author":"AA Herrada","year":"2010","unstructured":"Herrada AA, Contreras FJ, Marini NP, et al. aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol. 2010;184:191\u2013202. https:\/\/doi.org\/10.4049\/jimmunol.0802886.","journal-title":"J Immunol"},{"key":"1153_CR100","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/0014-2999(73)90232-X","volume":"21","author":"P Schmiedek","year":"1973","unstructured":"Schmiedek P, Sad\u00e9e W, Baethmann A. Cerebral uptake of a 3H-labelled spirolactone compound in the dog. Eur J Pharmacol. 1973;21:238\u201341. https:\/\/doi.org\/10.1016\/0014-2999(73)90232-X.","journal-title":"Eur J Pharmacol"},{"key":"1153_CR101","unstructured":"Pfizer Australia Pty Ltd. Australian Product Information - Aldactone\u00ae (spironolactone). Canberra, Australia: Therapeutic Goods Administration; 2022."},{"key":"1153_CR102","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1177\/095632029500600203","volume":"6","author":"P Ertl","year":"1995","unstructured":"Ertl P, Snowden W, Lowe D, et al. A comparative study of the in vitro and in vivo antiviral activities of acyclovir and penciclovir. Antivir Chem Chemother. 1995;6:89\u201397. https:\/\/doi.org\/10.1177\/095632029500600203.","journal-title":"Antivir Chem Chemother"},{"key":"1153_CR103","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1600-0404.2005.00516.x","volume":"112","author":"P H\u00f6llsberg","year":"2005","unstructured":"H\u00f6llsberg P, Kusk M, Bech E, et al. Presence of Epstein\u2013Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity. Acta Neurol Scand. 2005;112:395\u2013402. https:\/\/doi.org\/10.1111\/j.1600-0404.2005.00516.x.","journal-title":"Acta Neurol Scand"},{"key":"1153_CR104","doi-asserted-by":"publisher","DOI":"10.3651\/2689-0216.1241","author":"A DeRenzi","year":"2021","unstructured":"DeRenzi A, Penico J. Lymphoproliferative disease in a non-transplant patient and spironolactone\u2019s activity against Epstein\u2013Barr virus. HCA Healthc J Med. 2021. https:\/\/doi.org\/10.3651\/2689-0216.1241.","journal-title":"HCA Healthc J Med"},{"key":"1153_CR105","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/BF00316223","volume":"202","author":"J Mertin","year":"1972","unstructured":"Mertin J, Koczorek KhR, Backmund H. Pilot study on the efficacy of high doses of aldosterone and spirolactone derivatives in the treatment of multiple sclerosis. Z Neurol. 1972;202:217\u201328. https:\/\/doi.org\/10.1007\/BF00316223.","journal-title":"Z Neurol"},{"key":"1153_CR106","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jnnp-2020-324286","volume":"92","author":"N Cunniffe","year":"2021","unstructured":"Cunniffe N, Vuong KA, Ainslie D, et al. Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2021;92:295\u2013302. https:\/\/doi.org\/10.1136\/jnnp-2020-324286.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1153_CR107","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41579-022-00770-5","volume":"21","author":"SS Soldan","year":"2023","unstructured":"Soldan SS, Lieberman PM. Epstein\u2013Barr virus and multiple sclerosis. Nat Rev Microbiol. 2023;21:51\u201364. https:\/\/doi.org\/10.1038\/s41579-022-00770-5.","journal-title":"Nat Rev Microbiol"},{"key":"1153_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2016.87","volume":"6","author":"MP Pender","year":"2017","unstructured":"Pender MP, Csurhes PA, Burrows JM, Burrows SR. Defective T-cell control of Epstein\u2013Barr virus infection in multiple sclerosis. Clin Trans Immunol. 2017;6: e126. https:\/\/doi.org\/10.1038\/cti.2016.87.","journal-title":"Clin Trans Immunol"},{"key":"1153_CR109","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13027-023-00485-z","volume":"18","author":"CG Gottschalk","year":"2023","unstructured":"Gottschalk CG, Peterson D, Armstrong J, et al. Potential molecular mechanisms of chronic fatigue in long haul COVID and other viral diseases. Infect Agent Cancer. 2023;18:7. https:\/\/doi.org\/10.1186\/s13027-023-00485-z.","journal-title":"Infect Agent Cancer"},{"key":"1153_CR110","doi-asserted-by":"publisher","first-page":"226","DOI":"10.3390\/pathogens9030226","volume":"9","author":"MAH Abusalah","year":"2020","unstructured":"Abusalah MAH, Gan SH, Al-Hatamleh MAI, et al. Recent advances in diagnostic approaches for Epstein\u2013Barr virus. Pathogens. 2020;9:226. https:\/\/doi.org\/10.3390\/pathogens9030226.","journal-title":"Pathogens"},{"key":"1153_CR111","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104377","volume":"68","author":"J Gold","year":"2022","unstructured":"Gold J, Holden D, Parratt J, et al. Effect of teriflunomide on Epstein\u2013Barr virus shedding in relapsing-remitting multiple sclerosis patients: outcomes from a real-world pilot cohort study. Mult Scler Relat Disord. 2022;68: 104377. https:\/\/doi.org\/10.1016\/j.msard.2022.104377.","journal-title":"Mult Scler Relat Disord"},{"key":"1153_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101388","volume":"36","author":"R Zivadinov","year":"2019","unstructured":"Zivadinov R, Ramanathan M, Hagemeier J, et al. Teriflunomide\u2019s effect on humoral response to Epstein\u2013Barr virus and development of cortical gray matter pathology in multiple sclerosis. Mult Scler Relat Disord. 2019;36: 101388. https:\/\/doi.org\/10.1016\/j.msard.2019.101388.","journal-title":"Mult Scler Relat Disord"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01153-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01153-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01153-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T15:58:02Z","timestamp":1740412682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01153-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,10]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["1153"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01153-5","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,10]]},"assertion":[{"value":"10 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"V.L., F.McK., D.T., C.S., R.K., J.L.-S., A.L., B.T., J.M., L.S., G.G., S.S. and T.H. are recipients of or members of partner organisations on research grants for clinical trials of antiviral treatments for EBV in MS from the Australian Government Medical Research Future Fund (MRFF, 2023). D.T. has received research funding from the MRFF, Australian Research Council, the Australian National University and the Defence Materials Technology Centre. C.S. reports research and consultancy funding from Atara Biotherapeutics and has acted as a consultant for ATA188 program developing EBV immunotherapy for multiple sclerosis. He is a recipient of grants from MRFF and holds international patents or patent applications that cover CMV epitope sequences and their use in adoptive immunotherapy. R.K. is on the scientific advisory board of and is a consultant of Atara Biotherapeutics; is the editor-in-chief of Clinical and Translational Immunology; has patents or patents pending for T cell epitopes and immunotherapy for virus-associated diseases including malignancies and autoimmune diseases; received research support from Atara Biotherapeutics and National Health and Medical Research Council (NHMRC); and holds stock options in and received licensing payments from Atara Biotherapeutics. J.L.-S. has accepted travel compensation from Novartis, Biogen and Merck Healthcare KGaA (Darmstadt, Germany). Her institution receives the honoraria for talks and advisory board commitment as well as research grants from Janssen, Bayer Health Care, Biogen Idec, CSL, Celgene (BMS), Sanofi Genzyme, Merck, Roche, TEVA and Novartis. W.R. reports no disclosures relevant to the manuscript. A.L. has received investigator- initiated research grants from Gilead, Abbvie, Merck and Bristol-Myers Squibb. He has received investigator-initiated research grants from AbbVie, Gilead Sciences and Sequiris. He is supported by a Fellowship from NHMRC. B.T. or his institute have received honoraria for speaking from Merck and Novartis. He has served on advisory boards for Merck and Novartis and serves on the Australian National Blood Authority Scientific Working Group. L.S. has issued patents and an ongoing application for DNA vaccines for tolerance to myelin antigens, including GlialCAM (Pasithea Therapeutics) and has patent filings regarding antivirals for the treatment of MS. He is the principal investigator at Stanford University in the ATA188 trial with cell-based therapy for progressive MS. He has acted as a consultant for TG Therapeutics, 180 Life Sciences, BioAtla, Pasithea and Atreca; and is on Advisory or Data Safety Monitoring Boards for TG Therapeutics, Novartis, Receptos, Atreca, Tolerion, Teva and AbbVie; received travel funding and\/or speaker honoraria from Celgene and AbbVie; received research support from Atara Biotherapeutics, Celgene and Biogen; holds stock options and board membership in Tolerion; and is a member of the board of directors of BioAtla. G.G. has received consulting or speaker fees from AbbVie, Aslan, Atara Bio, Biogen, Bristol Myers Squibb\u2013Celgene, GlaxoSmithKline, GW Pharma, Janssen\u2013Actelion, Japanese Tobacco, Jazz Pharmaceuticals, LifNano, Merck and Co, Merck KGaA\u2013EMD Serono, Moderna, Novartis, Sanofi Genzyme, Roche-Genentech and Teva Pharmaceuticals. A.B.-O. has participated as a speaker in meetings sponsored by and received consulting fees and\/or grant support from: Janssen\/Actelion; Atara Biotherapeutics, Biogen Idec, Celgene\/Receptos, Roche\/Genentech, Medimmune, Merck\/EMD Serono, Novartis and Sanofi-Genzyme. He has served on the scientific advisory boards of Receptos-Celgene, Sanofi\/Genzyme, Roche\/Genentech, Novartis, GSK, Atara Therapeutics, Guthy-Jackson Greater Good Foundation and Immune Tolerance Network. M.L. has received consulting fees from Alexion, Viela Bio, Genentech\/Roche\/Chugai, Quest Diagnostics and UCB Pharmaceuticals. N.D., A.P., N.C., L.S., E.B. and B.F. report no disclosures relevant to the manuscript. S.H. serves on advisory boards for Merck Healthcare KGaA (Darmstadt, Germany), Biogen, Novartis, Sanofi, Roche and Bayer. She has received money for travel and speaker honorarium from Biogen, Sanofi, Novartis, Merck Healthcare KGaA (Darmstadt, Germany), Roche and Bayer. T.H. has received speaking fees or received honoraria for serving on advisory boards for Bayer, Biogen, Merck, Teva, Novartis, Roche, Bristol Myers Squibb and Sanofi-Genzyme. S.B. has received honoraria for attendance at advisory boards and travel sponsorship from Bayer-Schering, Biogen-Idec, Merck-Serono, Novartis, and Sanofi-Genzyme, TEVA and CSL; has received speakers\u2019 honoraria from Biogen-Idec and Genzyme; is an investigator in clinical trials sponsored by Biogen Idec, Novartis and Genzyme and ATARA; and was the recipient of an unencumbered research grant from Biogen-Idec.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Data supporting the findings of this study are provided in the Online Resource file.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"No funding was received to assist with the preparation of this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The study was approved by the Griffith University Human Research Ethics Committee, GU2024\/155 and conducted in accordance with principles of the 1964 Declaration of Helsinki and its later amendments.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not Applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"S.B. conceived the idea; S.B., S.H. and G.G. proposed drug candidates for consideration from existing reviews; V.L. and F.McK. prepared scientific and plain language drug summaries; V.L., wrote the first draft of the manuscript; S.B., V.L. and F.McK. analysed the data; A.P., N.C., L.S., E.B. and B.F. reviewed plain language summaries and completed detailed tolerability surveys. The expert scientific committee included S.B., V.L., D.T., R.K., C.S., W.R., A.L., B.T., L.S., G.G., J.L.-S., S.H. and T.H. All authors revised and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}